Yeh & Valsdottir et al, "Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial", British Medical Journal (BMJ 2018;363:k5094)
"Should our results be reproduced in future studies, the end of routine parachute use during jumps from aircraft could save the global economy billions of dollars spent annually to prevent injuries related to gravitational challenge."
Objective: To determine if using a parachute prevents death or major traumatic injury when jumping from an aircraft.
Design: Randomized controlled trial.
Setting: Private or commercial aircraft between September 2017 and August 2018.
Participants: 92 aircraft passengers aged 18 and over were screened for participation. 23 agreed to be enrolled and were randomized.
Intervention: Jumping from an aircraft (airplane or helicopter) with a parachute versus an empty backpack (unblinded).
Main Outcome Measures: Composite of death or major traumatic injury (defined by an Injury Severity Score over 15) upon impact with the ground measured immediately after landing.
Results: Parachute use did not significantly reduce death or major injury (0% for parachute v 0% for control; P>0.9). This finding was consistent across multiple subgroups. Compared with individuals screened but not enrolled, participants included in the study were on aircraft at significantly lower altitude (mean of 0.6 m for participants v mean of 9146 m for non-participants; P<0.001) and lower velocity (mean of 0 km/h v mean of 800 km/h; P<0.001).
Conclusions: Parachute use did not reduce death or major traumatic injury when jumping from aircraft in the first randomized evaluation of this intervention. However, the trial was only able to enroll participants on small stationary aircraft on the ground, suggesting cautious extrapolation to high altitude jumps. When beliefs regarding the effectiveness of an intervention exist in the community, randomized trials might selectively enroll individuals with a lower perceived likelihood of benefit, thus diminishing the applicability of the results to clinical practice.
[JC: Yes, it's satire, but it's beautifully done, isn't it? Dr. Thomas Borody—of the CoViD-19 "Australian Triple Therapy"—mentions it in this interview, as he criticises the current fetishisation of the "randomised controlled trial" and some of the deadly RCTs trials on HCQ that have been conducted in recent times.]
"Professor Thomas Borody Interview – Part 2", Covexit New and Analysis YouTube channel (10/22 September 2020)
(Please only play this video if you are happy for YouTube to place cookies on your computer.)
(The above article abstract is reproduced here under its CC BY-NC 4.0 licence.)